CEPROTIN

Copyright 2019 Takeda Pharmaceutical Company Limited. 1-800-828-2088. All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. CEPROTIN is a registered trademark of Baxalta Incorporated, a Takeda company... The pivotal study was a multi-center, open-label, non-randomized study in 3 parts which evaluated the safety and efficacy of CEPROTIN in patients with severe congenital protein C deficiency for the (on-demand) treatment of acute thrombotic episodes, such as purpura fulminans (PF), and other thromboembolic events, and for short-term or long-term prophylaxis. 18 patients (9 male and 9 female), ages ranging from 0 (newborn) to 25.7 years participated in this study. 1

Also known as: Baxalta, Baxalta Incorporated